Tempus AI (NASDAQ:TEM) CEO Sells $25,456,200.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 332,500 shares of the company’s stock in a transaction on Thursday, September 25th. The shares were sold at an average price of $76.56, for a total value of $25,456,200.00. Following the completion of the transaction, the chief executive officer owned 9,141,032 shares of the company’s stock, valued at $699,837,409.92. The trade was a 3.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Tempus AI Stock Performance

Shares of NASDAQ:TEM opened at $78.57 on Tuesday. The firm has a market capitalization of $13.65 billion, a PE ratio of -66.03 and a beta of 5.08. The company has a debt-to-equity ratio of 2.58, a current ratio of 1.54 and a quick ratio of 1.43. The business has a 50-day moving average of $73.06 and a two-hundred day moving average of $62.29. Tempus AI, Inc. has a 12 month low of $31.36 and a 12 month high of $97.79.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $314.64 million during the quarter, compared to the consensus estimate of $296.84 million. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The company’s revenue was up 89.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($6.86) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on TEM shares. Needham & Company LLC reissued a “buy” rating and issued a $70.00 price target on shares of Tempus AI in a report on Friday, August 8th. Bank of America upped their price objective on Tempus AI from $68.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, June 25th. Morgan Stanley raised their price target on Tempus AI from $65.00 to $68.00 and gave the stock an “overweight” rating in a report on Tuesday, August 12th. HC Wainwright raised their price target on Tempus AI from $90.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Finally, Guggenheim raised their target price on Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Friday. Seven equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $71.83.

Hedge Funds Weigh In On Tempus AI

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Concord Wealth Partners boosted its stake in Tempus AI by 308.0% during the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after purchasing an additional 308 shares in the last quarter. Allworth Financial LP boosted its stake in shares of Tempus AI by 5,000.0% during the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after acquiring an additional 450 shares in the last quarter. SouthState Corp boosted its stake in shares of Tempus AI by 3,761.5% during the 2nd quarter. SouthState Corp now owns 502 shares of the company’s stock worth $32,000 after acquiring an additional 489 shares in the last quarter. Cherry Tree Wealth Management LLC bought a new stake in shares of Tempus AI during the 1st quarter worth $31,000. Finally, University of Texas Texas AM Investment Management Co. bought a new stake in shares of Tempus AI during the 1st quarter worth $33,000. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.